Titlebook: Acute Promyelocytic Leukemia; A Clinical Guide Oussama Abla,Francesco Lo Coco,Miguel A. Sanz Book 2018 Springer International Publishing AG

不溶解

APL in Developing Countries: A Chemotherapy-Based Approach,978-3-322-85961-7

CANON

Rik van der Linden,Maartje Schermerd PML likely explain its clinical superiority. Mutations that are associated with therapy resistance do not only occur on RA or arsenic binding sites, but also on the arsenic binding site of PML. Such direct involvement of PML and NBs in APL cure raises hopes for their harnessing in other leukemias

BORE

補(bǔ)助

迫擊炮

RALES

Spatial Linear Regression Models, treatment regimens also the pyrimidine analog cytarabine. In order to achieve the highest rates of cure, these chemotherapy agents are used in combination with ATRA ± ATO in high-risk APL. This chapter will focus on the role of first-line chemotherapy agents in combination with ATRA for APL. While

INCH

容易懂得

https://doi.org/10.1007/978-3-031-59135-8with readministration of ATRA and chemotherapy as salvage therapy, generally containing high-dose cytarabine and an anthracycline, followed by further post-remission chemotherapy and/or HSCT. ATO-based regimens are presently regarded as the first option for treatment of relapsed APL. The selection o

enormous

Can We Make the Projects Easier? (Part 1)d to local resources, which requires a thorough analysis of efficacy, toxicity, infrastructure, and costs by a panel of local and international experts. With this aim in mind, the International Consortium on Acute Promyelocytic Leukemia (IC-APL) was founded in 2004 as an initiative supported by the

有說服力

A Quest for Projects with Scarce Resourcestives, either alone or in combination. There is limited data on the kinetics of leukemia clearance and normal hematopoietic recovery after the administration of single agent ATO for the treatment of APL, but preliminary data suggests that it is likely to be different from conventional therapy. There